News | Focused Ultrasound Therapy | May 04, 2017

U.S. Clinical Data Supports Echotherapy With Echopulse for Breast Fibroadenomas

Data presented at American Society of Breast Surgeons meeting shows echotherapy was well-tolerated and resulted in minimal side effects

U.S. Clinical Data Supports Echotherapy With Echopulse for Breast Fibroadenomas

May 4, 2017 — Theraclion recently announced the presentation of data from the U.S. feasibility trial of echotherapy with Echopulse, a non-invasive treatment employing ultrasound-guided high-intensity focused ultrasound (HIFU), in women with breast fibroadenomas. Results were presented at The American Society of Breast Surgeons (ASBrS) Annual Meeting, held April 26-30 in Las Vegas.

The single-arm feasibility study was led by David Brenin, M.D., chief of breast surgery, co-director of the University of Virginia Breast Care Program, associate professor of surgery at UVA’s School of Medicine and principal investigator of the ongoing pivotal trial. The study enrolled 20 patients with 1 cm or larger palpable breast fibroadenomas to assess the safety and feasibility of a single Echopulse treatment. Fifty percent of patients reported a painful mass prior to enrollment. The study showed that echotherapy was well-tolerated. Pain and discomfort were the most commonly-reported side effects but remained minimal. Patient satisfaction after three months was 4.4 and the likelihood that they would recommend the treatment to a friend or family member was 4.7 (scale of 1-5, in which 5 indicated most satisfied). Long-term cosmetic outcome, reduction in breast fibroadenoma size and patient experience are currently under investigation.

Following this initial feasibility study, Theraclion has recently launched a U.S. pivotal trial evaluating the safety and efficacy of Echopulse. The pivotal trial is currently enrolling patients and is also being led by Brenin. The trial will enroll approximately 100 patients at four centers in the United States — University of Virginia School of Medicine, NYU Langone Bellevue, Montefiore Medical Center (NY) and New York-Presbyterian/Columbia University Medical Center — and two in Europe with Tübingen University Hospital, Germany and the University Hospital of Endocrinology in Sofia, Bulgaria.

Brenin said, “Although benign, breast fibroadenomas can cause discomfort, and the discovery of a lump in their breast can create anxiety in women. The current standard of care is surgery, which can cause significant pain and discomfort requiring medication and inevitably leads to scar formation. Echopulse is a very promising non-invasive alternative approach to treat the condition without the complications of surgery.”

Theraclion Chief Medical Officer Michel Nuta, M.D., said the results are consistent with clinical evaluations performed in Europe, where Echopulse is currently indicated with a CE Mark for this condition. Nuta said the company anticipates announcing top-line results for the U.S. clinical trial in 2019.

For more information: www.theraclion.com

Related Content

Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...